GLP1R and type 2 diabetes mellitus: Compared with GLP-1 RA monotherapy, combination therapy with SGLT2i and GLP-1 RA was associated with lower risk of HF-related outcomes (RR 0.63, 95% CI: 0.51–0.77, p < 0.001) and all-cause mortality (RR 0.66, 95% CI: 0.50–0.88, p = 0.004) in patients with type 2 diabetes [86].